Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy
Clinical and Translational Science · 2025-04 · 18 (4)
DOI: 10.1111/cts.70212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 22.04.2025. Verfasst von Gatadi Srikanth und 5 weiteren Autor:innen. Beteiligte Einrichtung: GITAM School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, India. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Immunologic, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SEED, Science for Equity, Empowerment and Development Division.
Abstract (Originalsprache)
TIGIT (T cell immunoreceptor with immunoglobulin and tyrosine‐based inhibitory motif (ITIM) domain), Vstm3, and VSIG9, are newly recognized immunological checkpoints. They are prominently expressed on CD4+ and CD8+ T cells, tumor‐infiltrating lymphocytes (TILs), natural killer (NK) cells, and regulatory T cells (Tregs). The TIGIT (TIGIT) protein is crucial for immune modulation since it diminishes NK cell populations and hinders T cell activity in cancer patients and experimental models. CD155, the principal ligand of TIGIT in humans, has been recognized as a pivotal target for immunotherapy owing to its interaction with TIGIT. CD155 is linked to the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy, even without TIGIT expression, underscoring its importance in immune checkpoint suppression. Anti‐TIGIT medicines, either independently or in conjunction with anti‐PD‐1 treatments, have demonstrated potential in augmenting immune responses to malignancies. This review examines the structural and functional characteristics of the TIGIT protein, new developments in anti‐TIGIT drugs, and their prospective use in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GITAM School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, India.
- Chemistry Division, Innatura Scientific Pvt. Ltd., Hyderabad, Telangana, India.
- Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
- Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education, (Deemed to Be University), Wardha, Maharashtra, India.
ORCID-Profile: Gatadi Srikanth, Jitendra Patel
Förderung
- SEED
- Science for Equity, Empowerment and Development Division
Zitieren
APA
Srikanth, G., Beda, D. P., Dwivedi, A. R., Duddukuri, N. K., Nanduri, S., & Patel, J. (2025). Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy. Clinical and Translational Science, 18(4). https://doi.org/10.1111/cts.70212
Vancouver
Srikanth G, Beda DP, Dwivedi AR, Duddukuri NK, Nanduri S, Patel J. Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy. Clinical and Translational Science. 2025;18(4). doi:10.1111/cts.70212
BibTeX
@article{Srikanth2025,
author = {Srikanth, Gatadi and Beda, Durga Prasad and Dwivedi, Ashish Ranjan and Duddukuri, Nandan Kumar and Nanduri, Srinivas and Patel, Jitendra},
title = {Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {4},
doi = {10.1111/cts.70212}
}
EUVIMED